Arvinas Inc (ARVN)
24.85
-1.13
(-4.35%)
USD |
NASDAQ |
Jul 02, 16:00
24.65
-0.20
(-0.80%)
After-Hours: 20:00
Arvinas SG&A Expense (TTM): 99.60M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 99.60M |
December 31, 2023 | 100.20M |
September 30, 2023 | 88.30M |
June 30, 2023 | 85.70M |
March 31, 2023 | 84.30M |
December 31, 2022 | 79.60M |
September 30, 2022 | 83.30M |
June 30, 2022 | 79.30M |
March 31, 2022 | 69.40M |
December 31, 2021 | 61.50M |
September 30, 2021 | 54.93M |
June 30, 2021 | 48.26M |
Date | Value |
---|---|
March 31, 2021 | 42.68M |
December 31, 2020 | 38.30M |
September 30, 2020 | 33.33M |
June 30, 2020 | 31.96M |
March 31, 2020 | 29.58M |
December 31, 2019 | 27.30M |
September 30, 2019 | 25.86M |
June 30, 2019 | 22.19M |
March 31, 2019 | 17.33M |
December 31, 2018 | 12.93M |
September 30, 2018 | 8.300M |
June 30, 2018 | 4.873M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
25.86M
Minimum
Sep 2019
100.20M
Maximum
Dec 2023
61.23M
Average
61.50M
Median
Dec 2021
SG&A Expense (TTM) Benchmarks
Pfizer Inc | 14.85B |
BridgeBio Pharma Inc | 185.29M |
Alnylam Pharmaceuticals Inc | 822.78M |
Agios Pharmaceuticals Inc | 122.55M |
Krystal Biotech Inc | 100.42M |